92 related articles for article (PubMed ID: 3622309)
1. Cyclandelate. An inhibitor of cholesterol esterification.
Middleton B; Cacciaguerra F; White D
Drugs; 1987; 33 Suppl 2():75-9. PubMed ID: 3622309
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acyl coenzyme A: cholesterol acyl transferase by trimethylcyclohexanylmandelate (cyclandelate).
Heffron F; Middleton B; White DA
Biochem Pharmacol; 1990 Feb; 39(3):575-80. PubMed ID: 2306268
[TBL] [Abstract][Full Text] [Related]
3. The effects of two acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density lipoprotein metabolism in macrophages and hepatocytes.
White DA; Heffron F; Knight D; Salter AM
Biochem Pharmacol; 1994 Aug; 48(5):915-22. PubMed ID: 8093104
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of cholesterol esterification by cyclandelate in transformed mouse macrophages.
Heffron F; Middleton B; White DA
Biochem Pharmacol; 1993 May; 45(9):1829-34. PubMed ID: 8494541
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cellular cholesterol esterification can decrease low density lipoprotein receptor number in human fibroblasts.
Middleton B
Biochem Biophys Res Commun; 1987 May; 145(1):350-6. PubMed ID: 3593342
[TBL] [Abstract][Full Text] [Related]
6. In vivo inhibition of hepatic lipogenesis in the rat by cyclandelate (3,3',5-trimethylcyclohexanylmandelate).
Middleton A; White DA; Bell GD; Middleton B
Biochem Pharmacol; 1983 Oct; 32(20):3079-83. PubMed ID: 6639676
[TBL] [Abstract][Full Text] [Related]
7. The role of cholesterol esterification in ovarian steroidogenesis: studies in cultured swine granulosa cells using a novel inhibitor of acyl coenzyme A: cholesterol acyltransferase.
Veldhuis JD; Strauss JF; Silavin SL; Kolp LA
Endocrinology; 1985 Jan; 116(1):25-30. PubMed ID: 3917248
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate.
Middleton B; Middleton A; Miciak A; White DA; Bell GD
Biochem Pharmacol; 1983 Feb; 32(4):649-51. PubMed ID: 6681959
[TBL] [Abstract][Full Text] [Related]
9. The effect of cyclandelate on cholesterol synthesis.
Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
[No Abstract] [Full Text] [Related]
10. Cyclandelate as a calcium modulating agent in rat cerebral cortex.
Bast A; Leurs R; Timmerman H
Drugs; 1987; 33 Suppl 2():67-74. PubMed ID: 3040372
[TBL] [Abstract][Full Text] [Related]
11. The influence of cyclandelate on Ca++ translocation in human platelets.
Akkerman JW; van den Hoven WE
Drugs; 1987; 33 Suppl 2():53-9. PubMed ID: 3622308
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages.
Cignarella A; Brennhausen B; von Eckardstein A; Assmann G; Cullen P
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1322-9. PubMed ID: 9714140
[TBL] [Abstract][Full Text] [Related]
13. Chemical synthesis of dual-radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells.
White DA; Heffron F; Miciak A; Middleton B; Knights S; Knight D
Xenobiotica; 1990 Jan; 20(1):71-9. PubMed ID: 2327109
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
de Medina P; Payré BL; Bernad J; Bosser I; Pipy B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1165-73. PubMed ID: 14617686
[TBL] [Abstract][Full Text] [Related]
15. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
Timmerman H
Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
[No Abstract] [Full Text] [Related]
16. [Effect of the monooxygenase activity inhibitor ketoconazole on cholesterol esterification in mouse peritoneal macrophages].
Dushkin MI; Mandrikova EV; Liubimov GIu; Vol'skiĭ NN; Dolgov AV
Biokhimiia; 1990 Sep; 55(9):1607-15. PubMed ID: 2078637
[TBL] [Abstract][Full Text] [Related]
17. The antihypertensive drug propranolol enhances LDL catabolism and alters cholesterol metabolism in human cultured fibroblasts.
Mazière C; Mazière JC; Salmon S; Mora L; Auclair M
Atherosclerosis; 1990 Mar; 81(2):151-60. PubMed ID: 2322324
[TBL] [Abstract][Full Text] [Related]
18. The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells.
Mazière JC; Mazière C; Auclair M; Mora L; Arnaud O
Eur J Clin Pharmacol; 1991; 41(4):339-44. PubMed ID: 1666560
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
Van den Hoven WE; Hall DW; Burns JW
Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
[No Abstract] [Full Text] [Related]
20. Influence of cyclandelate on in vitro red blood cell deformability.
Hall DW; van den Hoven WE
Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
